Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease marked by cholestasis and progressive fibrosis. While ursodeoxycholic acid (UDCA) remains the first-line therapy, approximately 30–40% of patients have an inadequate biochemical response, increasing the risk of disease progressi...

詳細記述

書誌詳細

主要な著者:	Fares Jamal, Amani Elshaer, Mayar H. Alatout, Nour B. Odeh, Amal Youssef, Humam Abo Abdullah, Sandra Elmasry, Tala Shahin, Hussein Abdul Nabi, Astin R. Worden, Talha A. Malik, Blanca C. Lizaola-Mayo
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2025-09-01
シリーズ:	Biomedicines
主題:	primary biliary cholangitis second-line therapy obeticholic acid fenofibrate seladelpar elafibranor
オンライン･アクセス:	https://www.mdpi.com/2227-9059/13/10/2335
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!